Skip navigation

Know earlier if your immunotherapy is working

Your cancer needs to be managed with personalized treatment and a plan unique to you. If you are being treated with immune checkpoint inhibitors (ICIs), a type of immunotherapy, you may have questions about whether the treatment is working for you.
Signatera is a new blood test that uses your unique set of tumor mutations to monitor your cancer. Signatera can tell you earlier than traditional tests whether small amounts of cancer are still in your body and if your cancer is likely to come back. Knowing this information earlier can help you have a more informed discussion with your doctor regarding your immunotherapy treatment and follow-up plans.

As I continue my battle with cancer, I have learned that we must be our own advocates and work with our doctors as a team.



Learn how Signatera detects your cancer

Learn how Signatera works


A one-time analysis of both blood and tissue determines your unique set of tumor mutations.


The test is custom-built and personalized for you.


Signatera detects the presence or absence of cancer each time it is ordered as part of your routine follow-up blood tests.

Understand your Signatera test results

Your test results will either be positive or negative for the presence of circulating tumor DNA (ctDNA) in your blood. Your doctor will receive the test report and discuss your results and answer questions.
IMPORTANT: Negative results may change over time. A negative Signatera result doesn’t guarantee that tumor DNA is not in your blood, or that it will never be detected in the future. This is why ongoing monitoring with the Signatera test over the course of your cancer care, as directed by your doctor, is recommended for early detection of residual disease
Negative result
A negative result indicates that tumor DNA was not detected in your blood. This means you are more likely to remain cancer-free if you were diagnosed with early stage cancer.
If you have metastatic cancer, a negative result may mean your treatment was able to decrease the number of cancer cells to undetectable levels, meaning the treatment has been effective.
Positive result
A positive result indicates that tumor DNA has been detected in your blood and means there is higher risk for your cancer returning if you were diagnosed with early-stage cancer. Your doctor may continue to monitor your ctDNA levels to assess your tumor’s response to treatment.
Logo_Bespoke_IO_20201005 1

Discover our BESPOKE study of Signatera-guided immuno-oncology (IO) therapy

Be a part of something truly groundbreaking. Join Natera’s BESPOKE IO study to make a difference for people who, like you, are managing cancer with immunotherapy or immuno-oncology (IO) treatment. The study will examine the use of Signatera and the impact it has on treatment decisions for clinical outcomes in cancer patients being treated through immunotherapy. The study will enroll more than 1,500 patients. Natera and its collaborators will collect data on clinical decisions, benefits, and outcomes from enrolled participants for up to two years.

Visit our Signatera BESPOKE IO page to learn more about joining the study.

Check out FAQs to learn more about Signatera

Questions about Signatera?
Submit your inquiries here.